MENU
+Compare
ABUS
Stock ticker: NASDAQ
AS OF
Dec 24 closing price
Price
$4.79
Change
+$0.11 (+2.35%)
Capitalization
921.23M

ABUS Arbutus Biopharma Corp Forecast, Technical & Fundamental Analysis

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases... Show more

Industry: #Biotechnology
ABUS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ABUS with price predictions
Dec 24, 2025

ABUS sees its Stochastic Oscillator ascends from oversold territory

On December 23, 2025, the Stochastic Oscillator for ABUS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 04, 2025. You may want to consider a long position or call options on ABUS as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ABUS just turned positive on December 08, 2025. Looking at past instances where ABUS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

ABUS moved above its 50-day moving average on December 22, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABUS crossed bullishly above the 50-day moving average on December 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 233 cases where ABUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ABUS moved out of overbought territory on December 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ABUS broke above its upper Bollinger Band on December 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.905) is normal, around the industry mean (26.541). P/E Ratio (0.000) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (62.500) is also within normal values, averaging (311.015).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ABUS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ABUS is expected to report earnings to fall 25.00% to -2 cents per share on February 26

Arbutus Biopharma Corp ABUS Stock Earnings Reports
Q4'25
Est.
$-0.03
Q3'25
Missed
by $0.01
Q2'25
Beat
by $0.05
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.02
The last earnings report on November 13 showed earnings per share of -3 cents, missing the estimate of -2 cents. With 770.13K shares outstanding, the current market capitalization sits at 921.23M.
A.I. Advisor
published General Information

General Information

a developer of drugs to improve the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
701 Veterans Circle
Phone
+1 267 469-0914
Employees
73
Web
http://www.arbutusbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PROVX19.110.07
+0.37%
Provident Trust Strategy
SFMIX35.270.05
+0.14%
American Beacon Stephens Mid-Cap Gr R5
ACFCX74.670.04
+0.05%
American Century Focused Dynamic Gr R
FKMCX47.49N/A
N/A
Fidelity Mid-Cap Stock K
GNXCX17.06N/A
N/A
AlphaCentric Robotics and Automation C

ABUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+2.35%
IDYA - ABUS
46%
Loosely correlated
+0.76%
ARWR - ABUS
45%
Loosely correlated
+0.40%
RARE - ABUS
43%
Loosely correlated
+1.32%
XENE - ABUS
43%
Loosely correlated
+1.06%
ARRY - ABUS
43%
Loosely correlated
+2.10%
More